Focus: Quantum Genomics is a French-based biotechnology company focused on small-molecule therapeutics in neurology and respiratory indications. The company operates primarily as a generics and specialty pharma player with a concentrated revenue base.
Profile data last refreshed 19h ago · AI intelligence enriched 1w ago
Growing — net +6 jobs in 30d
12 jobs added vs 6 removed. Steady team buildout.
No open roles listed right now. Follow Quantum Genomics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Benzodiazepine ANDA currently dominating projected revenue (54% concentration); launch execution critical to near-term viability.
Help build intelligence for Quantum Genomics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Quantum Genomics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Branded benzodiazepine facing imminent patent loss; Part D spending indicates established patient base but limited growth runway.
ANDA generic entry into temazepam market; minimal current spending suggests competitive or formulary constraints.
SSRI/5HT2 antagonist ANDA in large MDD market; pre-launch status limits near-term revenue contribution.
Post-exclusivity vasodilator; limited growth potential in mature hypertension market.
Generic benzodiazepine past loss-of-exclusivity; commoditized market position.
Duplicate post-LOE vasodilator entry; mature market with stable but limited growth.
Duplicate anxiety disorder ANDA; critical to 54% revenue concentration thesis.
123 discontinued, 17 duplicate formulations not shown
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub